2023 End-of-Year Review: CNS & Rare Disease Insights
)
)
‘Although it has definitely been a tricky and challenging year for neuroscience – and biopharma in general – there have been some amazing successes that are still worth celebrating.’
Working within the CNS & Rare Disease space for our Life Sciences team, Paula Doust Alba has had a busy year. In this video, she gives us her end-of-year review for 2023 – and while it hasn’t always been plain sailing, breakthroughs in Alzheimer’s have been particularly gratifying to note.
Check out this clip to hear Paula reflect on the demand for clinical talent and experienced CMOs, fundraising and development breakthroughs – in addition to her predictions for 2024!
- Insight
- Market Update
- Executive Search
)
Cristian joined Venari Partners in 2019 and specialises in executive search across digital health and healthtech. He works closely with emerging and high-growth businesses across the US and Europe, helping them build leadership teams to support their growth and commercial ambitions. His sector expertise spans SaaS, digital therapeutics, AI, virtual care, real-world evidence (RWE) and healthcare IT, with a focus on senior appointments across strategy, business development, operations and commercial functions. With extensive experience supporting healthtech companies through key stages of growth, Cristian advises on C-suite, VP and Director-level appointments, board recruitment and succession planning. He also provides specialist support with US go-to-market expansion for European businesses, alongside interim solutions, market mapping, compensation benchmarking and leadership and organisational assessments. Combining deep sector knowledge with an understanding of the challenges facing growing healthtech businesses, Cristian brings a considered approach to identifying leadership talent and supporting organisations through critical stages of development.
View Full Profile)
)
)
)
)
)
